Education, Science, Technology, Innovation and Life
Open Access
Sign In

Treatment of primary bile reflux gastritis and its clinical pathological analysis

Download as PDF

DOI: 10.23977/meb.2019.1207

Author(s)

Shi Min

Corresponding Author

Shi Min

ABSTRACT

Objective: to analyze the effect of multiple therapies in the treatment of primary bile reflux, and to observe and analyze the pathological symptoms of bile reflux gastritis. Methods 120 cases from January 2016 to January 2017 in our hospital to receive treatment and meet the requirements of the patients, randomly divided into two groups, will give hydrotalcite and Weifuchun for treatment of patients in the treatment group were treated with Mosapride for treatment of patients as the control group, the treatment effect of the two groups of comparison. Results the two groups of patients after treatment of gastric reflux and the total number of reflux total time percentage decreases, but the change in the treatment group than the control group significantly (p<0.05); there was no significant difference in patients with pathological changes occurred before and after treatment with (P >0.05); the patients in the treatment group the total effective rate was 98.3%, the recurrence rate was 3.3%, control group total effective rate was 90%, the recurrence rate was 23.3%, the difference was statistically significant (p<0.05). In the conclusion of primary bile reflux gastritis patients were treated in the process, methods of hydrotalcite, Weifuchun multiple treatment can achieve better clinical effect, and the recurrence is low, the prognosis is good. In addition, according to the clinical pathological analysis results, primary bile reflux gastritis and gastric mucosa, intestinal metaplasia or dysplasia appeared atrophy associated changes.

KEYWORDS

Bile reflux gastritis, hydrotalcite, Weifuchun group, mosapride group, pathological analysis

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.